Skip to main content

Takeda trial for Crohn’s Perianal Fistulas treatment misses primary endpoint

Takeda said Tuesday its trial of darvadstrocel in the treatment of complex Crohn's Perianal Fistulas didn't meet its primary endpoint based on topline data.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.